Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis

Table 4 Plasma protein concentrations (fmol/μL) at baseline and at 6 weeks after SSRIs treatment

Protein	Responder			Nonresponder			Responsiveness
	Mean ± SD		Uni-P^a	Mean ± SD		Uni-P^a	Uni-P^b	Multi-P^c
	At baseline	At 6 week	Uni-P^a	At baseline	At 6 week	Uni-P^a	Uni-P^b	Multi-P^c
N	19			16
AGP1	8325 ± 2672	7916 ± 2084	0.455	8014 ± 3334	7888 ± 2856	0.433	0.540	0.954
HGFA	5.44 ± 3.60	4.50 ± 1.64	0.374	4.00 ± 1.55	4.01 ± 1.53	0.968	0.141	0.193
LBP	28.8 ± 13.2	32.0 ± 9.58	0.290	33.6 ± 17.6	30.0 ± 9.54	0.706	0.362	0.053
Prothrombin	1485 ± 294	1499 ± 172	0.728	1450 ± 316	1405 ± 325	0.744	0.733	0.294
SeP	137 ± 37.1	148 ± 16.5	0.237	129 ± 36.9	122 ± 38.2	0.464	0.417	0.465
TBG	118 ± 27.9	129 ± 24.9	0.090	128 ± 36.9	124 ± 24.9	0.336	0.354	0.370
Transthyretin	6105 ± 1689	6448 ± 1444	0.361	6016 ± 1681	5864 ± 1867	0.585	0.876	0.351

HAM-D Hamilton Depression Rating Scale, SD standard deviation, SSRIs selective serotonin reuptake inhibitors
^aP-value from Wilcoxon signed rank test or paired T-test between at baseline and at 6 weeks in each response group
^bP-value from Mann–Whitney test or T-test between responders and nonresponders at baseline
^cMultivariable P-value from partial Spearman correlation analysis including clinical variables with P < 0.020 (HAM-D score at baseline, number of episode, and duration of current episode)

ISSN: 1479-5876